Salbutamol inhalation - Adamis Pharmaceuticals

Drug Profile

Salbutamol inhalation - Adamis Pharmaceuticals

Alternative Names: Albuterol HFA - Adamis Pharmaceuticals; Albuterol HFA aerosol - Adamis Pharmaceuticals; APC 2000; APC 2000 HFA; Salbutamol HFA - Adamis Pharmaceuticals; Salbutamol HFA aerosol - Adamis Pharmaceuticals

Latest Information Update: 08 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adamis Pharmaceuticals Corporation
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules; Tocolytics
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Asthma; Bronchospasm

Most Recent Events

  • 08 Feb 2017 Phase-II clinical trials in Bronchospasm in USA (Inhalation) (Adamis Pharmaceuticals pipeline, February 2017)
  • 16 Apr 2015 Adamis plans a phase III trial for Asthma
  • 01 Jan 2014 Phase-II clinical trials in Asthma (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top